Send to

Choose Destination
Onco Targets Ther. 2013 Dec 27;7:87-90. doi: 10.2147/OTT.S54843. eCollection 2013.

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.

Author information

Department of Cardiology, Respiratory Medicine and Nephrology, Hirosaki University Graduate School of Medicine, Zaifu-cho, Hirosaki, Japan.
Respiratory Medicine, Hachinohe City Hospital, Tamukaibishamontai, Hachinohe, Japan.
Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, Zaifu-cho, Hirosaki, Japan.
Hirosaki University, Health Administration Center, Bunkyo, Hirosaki, Japan.



Thymic carcinoma is a rare neoplasm of the thymus. Systemic chemotherapy is an important therapeutic modality for thymic carcinoma. However, no standard chemotherapy for this carcinoma has yet been established. The usefulness of second-line or later-line chemotherapy has remained unclear. A case of relapsed thymic carcinoma that was successfully treated by S-1 as second-line chemotherapy is reported herein.


A 73-year-old man diagnosed as having thymic carcinoma was treated with three cycles of first-line chemotherapy with ADOC (cisplatin, doxorubicin, vincristine, and cyclophosphamide) and additional radiotherapy (50 Gy). Since his serum cytokeratin 19 fragment level increased suddenly after 3 months of stable disease, he was considered to have progressive disease, and was given S-1 as chemotherapy. Two months later, he had partial response, and the S-1 treatment has been continued since July 2009. Progression-free survival of greater than 4 years was obtained with S-1.


A case of relapsed thymic carcinoma that was treated with S-1, and continues to show a long progression-free survival with good quality of life on treatment is described. S-1 might be an active agent against relapsed thymic carcinoma.


S-1; thymic carcinoma; thymidylate synthase

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center